Amity Institute of Biotechnology, Amity University Haryana, Gurugram (Manesar), 122413, India.
Clinical Microbiology and Infectious Diseases, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, 2193, South Africa.
Int Microbiol. 2022 Nov;25(4):769-779. doi: 10.1007/s10123-022-00262-9. Epub 2022 Jul 5.
Infections caused by Candida albicans are rising due to increment in drug resistance and a limited arsenal of conventional antifungal drugs. Thus, elucidating the novel antifungal targets still represent an alternative that could overcome the problem of multidrug resistance (MDR). In this study, we have uncovered the distinctive effect of aminophospholipid translocase (Drs2p) deletion on major MDR mechanisms of C. albicans. We determined that efflux activity was diminished in Δdrs2 mutant as revealed by extracellular rhodamine 6G (R6G) efflux and flow cytometry. Moreover, we further unveiled that Δdrs2 mutant displayed decreased ergosterol content and increased membrane fluidity. Furthermore, Drs2p deletion affects the virulence attributes and led to inhibited hyphal growth and reduced biofilm formation. Additionally, THP-1 cell lines' mediated host-pathogen interaction studies revealed that Δdrs2 mutant displayed enhanced phagocytosis and altered cytokine production leading to increased IL-6 and decreased IL-10 production. Taken together, the present study demonstrates the relevance of Drs2p in C. albicans and consequently disrupting pathways known for mediating drug resistance and immune recognition. Comprehensive studies are further required to authenticate Drs2p as a novel antifungal drug target.
由于耐药性的增加和常规抗真菌药物的有限武器库,白色念珠菌引起的感染正在增加。因此,阐明新的抗真菌靶标仍然是一种可以克服多药耐药性(MDR)问题的选择。在这项研究中,我们发现了氨基磷脂转位酶(Drs2p)缺失对白色念珠菌主要 MDR 机制的独特影响。我们确定Δdrs2 突变体的外排活性降低,这是通过细胞外罗丹明 6G(R6G)外排和流式细胞术揭示的。此外,我们进一步揭示了Δdrs2 突变体显示出减少的麦角固醇含量和增加的膜流动性。此外,Drs2p 缺失会影响毒力特性,导致菌丝生长受到抑制和生物膜形成减少。此外,THP-1 细胞系介导的宿主-病原体相互作用研究表明,Δdrs2 突变体显示出增强的吞噬作用和改变的细胞因子产生,导致 IL-6 增加和 IL-10 减少。总之,本研究表明 Drs2p 在白色念珠菌中的相关性,并因此破坏了已知介导耐药性和免疫识别的途径。需要进一步的综合研究来验证 Drs2p 作为一种新的抗真菌药物靶标。